Skip to content
Menu
Network
Sub-Menu
Browse by Subject
Browse by Publisher
Join the Network
Get Started
Subscribe
Support
Contact Us
Search
Close
Enter Search Terms
Search
David Yi
ID:
1b839951-2619-30fb-68c4
/
Claimed Record
/
Organization:
Norton Rose Fulbright
Published Works
30 articles
FCA Confirms that Non-Infringing Alternative Must be Legal and Objectively Economically Viable
Pharma in Brief ·
December 20, 2018
cite
ONCA Permits Pleading Amendments Asserting Validity of Previously Invalidated Patent following Nexium Decision
Pharma in Brief ·
November 18, 2018
cite
Ontario Superior Court rejects Apotex attempts to revive the Promise Doctrine by dismissing motion for leave to amend, awards substantial indemnity costs
Pharma in Brief ·
November 18, 2018
cite
Pharma in Brief – Federal Court dismisses application for a prohibition order regarding prasugrel hydrochloride under the old PM(NOC) Regulations
Pharma in Brief ·
August 13, 2018
cite
ONCA upholds dismissal of summary judgment in lansoprazole s. 8 case
Pharma in Brief ·
April 19, 2018
cite
Previous
1
...
4
5
6
Next
Practice Areas
Health Care and Life Sciences
Jurisdictions
Canada
North America
